Skip to main content
MCK
NYSE Trade & Services

McKesson Q1 Earnings Beat, But Bottom Line Hit by Noncontrolling Charges; Restructuring and Apollo Deal Advance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Consumer
Sentiment info
Neutral
Importance info
8
Price
$896
Mkt Cap
$102.704B
52W Low
$637
52W High
$999
52W Position info
41% above low
Off High info
10% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

MCK sits 41% above its 52-week low of $637.

Summary

McKesson's fiscal Q1 revenue and adjusted EPS beat expectations, but GAAP earnings were weighed down by non-cash charges on redeemable noncontrolling interests. Restructuring costs surged as new efficiency programs were launched, while the Apollo deal for Medical-Surgical Solutions closed and capital returns remained aggressive.


Key Events · Earnings and Guidance · MCK

  • Revenue and Adjusted EPS Beat

    Revenue of $105.38 billion and adjusted EPS of $9.93 exceeded consensus estimates, driven by market growth in North American Pharmaceutical and Oncology & Multispecialty segments.

  • GAAP EPS Dragged by Noncontrolling Interest Charges

    Net income attributable to McKesson fell 22% to $614 million, or $5.15 per diluted share, primarily due to $374 million in non-cash redemption value adjustments on redeemable noncontrolling interests from Core Ventures and Medical-Surgical Solutions.

  • Restructuring Charges Surge

    Restructuring, impairment, and related charges totaled $136 million, up from $47 million a year ago, as the company initiated new multi-year efficiency programs in Corporate and Prescription Technology Solutions.

  • Apollo Minority Investment in Medical-Surgical Solutions Closes

    On June 1, 2026, Apollo Funds acquired a 13% stake in the Medical-Surgical Solutions business for $1.25 billion in convertible preferred equity, a key step in the planned separation of the segment.


Analysis · MCK · Trade & Services

McKesson delivered a strong top-line quarter with revenue of $105.4 billion and adjusted EPS of $9.93, both comfortably ahead of consensus. However, GAAP net income attributable to McKesson fell 22% to $614 million, dragged down by $374 million in non-cash redemption value adjustments on redeemable noncontrolling interests tied to the Core Ventures and Medical-Surgical Solutions transactions. The quarter also saw a sharp increase in restructuring charges to $136 million as the company launched new efficiency programs. On the strategic front, the $1.25 billion Apollo minority investment in Medical-Surgical Solutions closed, and the company continued its aggressive capital return, repurchasing $2.5 billion in stock and raising the dividend 15%. The results underscore the complexity of McKesson's portfolio transformation — strong underlying operating momentum is being partially obscured by accounting charges and separation costs.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 44.9% of the 1407 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MCK was trading at $896.00 on NYSE in the Trade & Services sector, with a market capitalization of approximately $102.7B. The 52-week trading range was $637.00 to $999.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MCK - Latest Insights

MCK
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1,049.50
Real-time Price: $1,072.00 info
Change: +$22.50 (+2%) info
Market Cap: $124.985B info
MCK
Nov 04, 2026, 5:30 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1,060.30
Real-time Price: $1,072.00 info
Change: +$11.70 (+1%) info
Market Cap: $124.985B info
MCK
Nov 04, 2026, 4:10 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $1,069.44
Real-time Price: $1,072.00 info
Change: +$2.56 (+0.24%) info
Market Cap: $124.985B info
MCK
Oct 06, 2026, 8:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $915.45
Real-time Price: $1,072.00 info
Change: +$156.55 (+17%) info
Market Cap: $124.985B info
MCK
Oct 05, 2026, 4:03 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $915.96
Real-time Price: $1,072.00 info
Change: +$156.04 (+17%) info
Market Cap: $124.985B info